Henriques-Pons A, Vacani-Martins N, Dos Santos C, Meuser-Batista M
Front Immunol. 2025; 15:1503063.
PMID: 39931578
PMC: 11808282.
DOI: 10.3389/fimmu.2024.1503063.
Liao F, Xie J, Du R, Gao W, Lan L, Wang M
Viruses. 2023; 15(12).
PMID: 38140543
PMC: 10747539.
DOI: 10.3390/v15122302.
Chen X, Liu X, Jiang Y, Xia N, Liu C, Luo W
Front Immunol. 2023; 14:1106700.
PMID: 36936922
PMC: 10014547.
DOI: 10.3389/fimmu.2023.1106700.
Park S, Hahn Y
Clin Mol Hepatol. 2022; 29(1):65-76.
PMID: 35957546
PMC: 9845665.
DOI: 10.3350/cmh.2022.0032.
Afify S, Hassan G, Seno A, Seno M
Br J Cancer. 2022; 127(2):193-201.
PMID: 35292758
PMC: 9296522.
DOI: 10.1038/s41416-022-01775-w.
Targeting human Acyl-CoA:cholesterol acyltransferase as a dual viral and T cell metabolic checkpoint.
Schmidt N, Wing P, Diniz M, Pallett L, Swadling L, Harris J
Nat Commun. 2021; 12(1):2814.
PMID: 33990561
PMC: 8121939.
DOI: 10.1038/s41467-021-22967-7.
RNA Interference Therapy for Chronic Hepatitis B Predicts the Importance of Addressing Viral Integration When Developing Novel Cure Strategies.
Wooddell C, Gehring A, Yuen M, Given B
Viruses. 2021; 13(4).
PMID: 33808298
PMC: 8065501.
DOI: 10.3390/v13040581.
Designing the next-generation therapeutic vaccines to cure chronic hepatitis B: focus on antigen presentation, vaccine properties and effect measures.
Jansen D, Dou Y, de Wilde J, Woltman A, Buschow S
Clin Transl Immunology. 2021; 10(1):e1232.
PMID: 33489122
PMC: 7809700.
DOI: 10.1002/cti2.1232.
Hepatitis Delta Virus Acts as an Immunogenic Adjuvant in Hepatitis B Virus-Infected Hepatocytes.
Tham C, Kah J, Tan A, Volz T, Chia A, Giersch K
Cell Rep Med. 2020; 1(4):100060.
PMID: 33205065
PMC: 7659593.
DOI: 10.1016/j.xcrm.2020.100060.
Therapeutic applications of the selective high affinity ligand drug SH7139 extend beyond non-Hodgkin's lymphoma to many other types of solid cancers.
Balhorn R, Balhorn M
Oncotarget. 2020; 11(35):3315-3349.
PMID: 32934776
PMC: 7476732.
DOI: 10.18632/oncotarget.27709.
Pathogenetic Mechanisms of T Cell Dysfunction in Chronic HBV Infection and Related Therapeutic Approaches.
Fisicaro P, Barili V, Rossi M, Montali I, Vecchi A, Acerbi G
Front Immunol. 2020; 11:849.
PMID: 32477347
PMC: 7235343.
DOI: 10.3389/fimmu.2020.00849.
Heterogeneity of HBV-Specific CD8 T-Cell Failure: Implications for Immunotherapy.
Heim K, Neumann-Haefelin C, Thimme R, Hofmann M
Front Immunol. 2019; 10:2240.
PMID: 31620140
PMC: 6763562.
DOI: 10.3389/fimmu.2019.02240.
Spatiotemporal Differences in Presentation of CD8 T Cell Epitopes during Hepatitis B Virus Infection.
Khakpoor A, Ni Y, Chen A, Ho Z, Oei V, Yang N
J Virol. 2018; 93(4).
PMID: 30518652
PMC: 6364024.
DOI: 10.1128/JVI.01457-18.
Nonstimulatory peptide-MHC enhances human T-cell antigen-specific responses by amplifying proximal TCR signaling.
Zhao X, Sankaran S, Yap J, Too C, Ho Z, Dolton G
Nat Commun. 2018; 9(1):2716.
PMID: 30006605
PMC: 6045629.
DOI: 10.1038/s41467-018-05288-0.
Outcome of Antiviral Immunity in the Liver Is Shaped by the Level of Antigen Expressed in Infected Hepatocytes.
Manske K, Kallin N, Konig V, Schneider A, Kurz S, Bosch M
Hepatology. 2018; 68(6):2089-2105.
PMID: 29729204
PMC: 6585666.
DOI: 10.1002/hep.30080.
Natural killer cell activation contributes to hepatitis B viral control in a mouse model.
Tong S, Liu G, Li M, Li X, Liu Q, Peng H
Sci Rep. 2017; 7(1):314.
PMID: 28331190
PMC: 5428210.
DOI: 10.1038/s41598-017-00387-2.
The role of tumour necrosis factor in hepatitis B infection: Jekyll and Hyde.
Valaydon Z, Pellegrini M, Thompson A, Desmond P, Revill P, Ebert G
Clin Transl Immunology. 2017; 5(12):e115.
PMID: 28090316
PMC: 5192060.
DOI: 10.1038/cti.2016.68.
Intrahepatic regulation of antiviral T cell responses at initial stages of viral infection.
Liang Y, Kwota Z, Sun J
Int Immunopharmacol. 2016; 39:106-112.
PMID: 27459170
PMC: 5012950.
DOI: 10.1016/j.intimp.2016.07.021.
Stable Human Hepatoma Cell Lines for Efficient Regulated Expression of Nucleoside/Nucleotide Analog Resistant and Vaccine Escape Hepatitis B Virus Variants and Woolly Monkey Hepatitis B Virus.
Cheng X, Guan W, Sun S, Li B, Li H, Kang F
PLoS One. 2015; 10(12):e0145746.
PMID: 26699621
PMC: 4689378.
DOI: 10.1371/journal.pone.0145746.
MHC Class I Presented T Cell Epitopes as Potential Antigens for Therapeutic Vaccine against HBV Chronic Infection.
Comber J, Karabudak A, Shetty V, Testa J, Huang X, Philip R
Hepat Res Treat. 2014; 2014:860562.
PMID: 24971174
PMC: 4058288.
DOI: 10.1155/2014/860562.